Putting Patients First Blog
APRIL 14, 2025
While we recognize CMS intent to strengthen program integrity and reduce fraud, we are deeply concerned that several provisions in this rule will create obstacles to coverage, increase out-of-pocket costs, and disproportionately impact vulnerable populations.
Express Pharma
MARCH 16, 2025
On the global stage, AI and Machine Learning (ML) drove drug discovery and process optimisation, especially as large-scale pharma companies adopted AI for precision medicine. Building sophisticated laboratories, recruiting scientific talent, and collaborating with global research institutions are essential steps in this process.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Digital Pharmacist
JANUARY 26, 2023
Amazon RxPass Benefits There’s no denying that RxPass presents some rather enticing benefits for Prime members, which now is estimated to include 172 million Americans. Another potential problem is that patients might be considered non-compliant by their insurance company if they fill their medications out of network (ie: using RxPass).
pharmaphorum
SEPTEMBER 10, 2021
.” He blamed the poor performance on ” confusion, misinformation and controversy surrounding our data and the approval process.” Analysts think sales will be lacklustre ahead of the outcome of a review of coverage by the Center for Medicare and Medicaid Services (CMS), which isn’t expected until next year.
Putting Patients First Blog
SEPTEMBER 3, 2024
The NHC appreciates CMS’ efforts to gather patient-centered data as part of this ICR and its commitment to making the process more relevant for patients and patient organizations. While we acknowledge these improvements, it is important to note that some aspects of the data collection process may remain challenging.
pharmaphorum
OCTOBER 1, 2022
In this latest coverage, pharmaphorum speaks with Eugene Borukhovich. He expects to see many new faces presenting, speaking in panel discussions, and much more: “That’s where you get the real deal information, right? The impacts of this, as we’ve seen, are insurers are on an acquisition spree at the moment,” Borukhovich says.
pharmaphorum
AUGUST 31, 2021
Christopher Boone, global head of health economics and outcomes research at AbbVie, advises: “Evidence generation in drug development is ripe for innovation in the digital era and the expanded use of real-world evidence presents a clear enabler to saving time and money.
Expert insights. Personalized for you.
52 
Let's personalize your content